Structural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signaling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Samoshkin, Alexander ^a,b   Convertino, Marino ^c   Viet, Chi T ^d   Wieskopf, Jeffrey S ^a,b   Kambur, Oleg ^e   Marcovitz, Jaclyn ^a,b   Patel, Pinkal ^a,b   Stone, Laura S ^a,b   Kalso, Eija ^f   Mogil, Jeffrey S ^a,b   Schmidt, Brian L ^d   Maixner, William ^g   Dokholyan, Nikolay V ^c,g   Diatchenko, Luda ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CALCIUM; LIGAND; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PROTEIN BINDING;

ANIMAL; CHEMISTRY; CONFORMATION; GANGLION; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MOUSE; NERVE CELL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANALGESICS, OPIOID; ANIMALS; CALCIUM; GANGLIA; GENE EXPRESSION; HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEURONS; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84949638591     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18198     Document Type: Article

References (60)

1. Ballantyne, J. C. & Shin, N. S. Efficacy of opioids for chronic pain: a review of the evidence. Clin. J. Pain 24, 469-478 (2008).
2. Toblin, R. L., Mack, K. A., G. Perveen & Paulozzi, L. J. A population-based survey of chronic pain and its treatment with prescription drugs. Pain 152, 1249-1255 (2011).
3. Corbett, A. D., Henderson, G., McKnight A. T. & Paterson, S. J. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br. J. Pharmacol. 147, S153-S162 (2006).
4. Pasternak, G. W. & Pan, Y. X. Mu Opioids and Their Receptors: Evolution of a Concept. Pharmacological reviews 65, 1257-1317 (2013).
5. Convertino, M. et al. μ -Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids. Prog. Neuropsychopharmacol. Biol. Psychiatry 62, 61-67 (2015).
6. Gris, P. et al. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol. Pain 6, 33 (2010).
7. Majumdar, S. et al. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc. Natl. Acad. Sci. USA 108, 19778-19783 (2011).
8. Hague, C. et al. Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 101, 13762-13676 (2004).
9. Hudson, B. D., Hébert, T. E. & Kelly, M. E. Physical and functional interaction between CB1 cannabinoid receptors and β 2-adrenoceptors. Br. J. Pharmacol. 160, 627-642 (2010).
10. Liang, D.-Y. et al. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104, 1054-1062 (2006).
11. Liang, D.-Y., Shi, X., Li, X., Li, J. & Clark, J. D. The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav. Brain Res. 181, 118-126 (2007).
12. Collard, V. et al. Intraoperative esmolol infusion in the absence of opioids spares postoperative fentanyl in patients undergoing ambulatory laparoscopic cholecystectomy. Anesth. Analg. 105, 1255-1262 (2007).
13. Wanaka, A. et al. Immunocytochemical localization of beta-adrenergic receptors in the rat brain. Brain Res. 485, 125-140 (1989).
14. Mansour, A. et al. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Neurol. 350, 412-438 (1994).
15. Usoskin, D. et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat. Neurosci. 18, 145-53 (2015).
16. Gagnon, A. W., Kallal, L. & Benovic, J. L. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J. Biol. Chem. 273, 6976-6981 (1998).
17. Kohout, T. A. & Lefkowitz, R. J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9-18 (2003).
18. Macia, E., Partisani, M., Paleotti, O., Luton, F. & Franco M. Arf6 negatively controls the rapid recycling of the β 2 adrenergic receptor. J. Cell Sci. 125, 4026-4035 (2012).
19. Pierce, B. G. et al. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics 30, 1771-1773 (2014).
20. Dokholyan, N. V., Buldyrev, S. V., Stanley, H. E. & Shakhnovich, E. I. Discrete molecular dynamics studies of the folding of a proteinlike model. Fold. Des. 3, 577-587 (1998).
21. Shirvanyants, D., Ding, F., Tsao, D., Ramachandran, S. & Dokholyan, N. V. Discrete molecular dynamics: an efficient and versatile simulation method for fine protein characterization. J. Phys. Chem. B. 116, 8375-8382 (2012).
22. Manglik, A. et al. Crystal structure of the μ -opioid receptor bound to a morphinan antagonist. Nature 21, 321-326 (2012).
23. 2+ currents, but spares a sustained current. Neuron 6, 13-20 (1991).
24. Mogil, J. S. Animal models of pain: progress and challenges. Nat Rev Neurosci. 10, 283-294 (2009).
25. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14 (2009).
26. Gomes, I., Ijzerman, A. P., Ye, K., Maille, E. L. & Devi, L. A. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol. Pharmacol. 79, 1044-1052 (2011).
27. Jordan, B. A., Gomes, I., Rios, C., Filipovska, J. & Devi, L. A. Functional interactions between μ opioid and α 2A-adrenergic receptors. Mol. Pharmacol. 64, 1317-1324 (2003).
28. Balasubramanian, S., Teissére, J. A., Raju, D. V. & Hall, R. A. Hetero-oligomerization between GABAA and GABAB receptors regulates GABAB receptor trafficking. J. Biol. Chem. 279, 18840-18850 (2004).
29. Chow, K. B. et al. The truncated ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression. Mol. Cell. Endocrinol. 348, 247-254 (2012).
30. Takahashi, K. et al. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66, 9408-9419 (2006).
31. Marshall, F. H., Jones, K. A., Kaupmann, K. & Bettler, B. GABAB receptors-the first 7TM heterodimers. Trends Pharmacol. Sci. 20, 396-399 (1999).
32. Margeta-Mitrovic, M., Jan, Y. N. & Jan, L. Y. A trafficking checkpoint controls GABAB receptor heterodimerization. Neuron 2000, 27, 97-106.
33. Schroeder, J. E. & McCleskey, E. W. Inhibition of Ca2 + currents by a mu-opioid in a defined subset of rat sensory neurons. J. Neurosci. 13, 867-873 (1993).
34. Crain, S. M. & Shen, K. F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84, 121-131 (2000).
35. Xu, J. et al. Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs. Proc. Natl. Acad. Sci. USA 112, 279-284 (2015).
36. Lu, Z. et al. Mediation of opioid analgesia by a truncated 6-transmembrane GPCR. J. Clin. Invest. 125, 2026-20130 (2015).
37. Majumdar, S. et al. Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants. J. Med. Chem. 55, 6352-6362 (2012).
38. Arnold, J. M. et al. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced betaadrenoceptor responses in man. Br. J. Clin. Pharmacol. 19, 619-630 (1985).
39. Jefferson, D., Wharrad, H. J., Birmingham, A. T. & Patrick, J. M. The comparative effects of ICI 118551 and propranolol on essential tremor. Br. J. Clin. Pharmacol. 24, 729-734 (1987).
40. Hanratty, C. G., Silke, B. & Riddell J. G. Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods. Br. J. Clin. Pharmacol. 47, 157-166 (1999).
41. Chen, X. & Levine, J. D. Epinephrine-induced excitation and sensitization of rat C-fiber nociceptors. J. Pain 6, 439-446 (2005).
42. Khasar, S. G., McCarter, G. & Levine, J. D. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J. Neurophysiol. 81, 1104-1112 (1999).
43. Khasar, S. G., Green, P. G., Miao, F. J. & Levine, J. D. Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. Eur. J. Neurosci. 17, 909-915 (2003).
44. Baerwald, C. G. & Panayi, G. S. Neurohumoral mechanisms in rheumatoid arthritis. Scand. J. Rheumatol. 26, 1-3 (1997).
45. Coderre, T. J., Basbaum, A. I., Dallman, M. F., Helms, C. & Levine, J. D. Epinephrine Exacerbates Arthritis by An Action at Presynaptic B2-Adrenoceptors. Neuroscience 34, 521-523 (1990).
46. Kaplan, R., Robinson, C. A., Scavulli, J. F. & Vaughan, J. H. Propranolol and the Treatment of Rheumatoid-Arthritis. Arthritis Rheum. 23, 253-255 (1980).
47. Levine, J. D., Coderre, T. J., Helms, C. & Basbaum, A. I. Beta-2-Adrenergic Mechanisms in Experimental Arthritis. Proc. Natl. Acad. Sci. USA 85, 4553-4556 (1988).
48. Kihara, T. & Kaneto, H. Important role of adrenergic function in the development of analgesic tolerance to morphine in mice. Jpn. J. Pharmacol. 42, 419-423 (1986).
49. Mitra, S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J. Opioid Manag. 4, 123-130 (2008).
50. Ménard, L. et al. Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration. Biochemistry. 35, 4155-4160 (1996).
51. Malin, S. A., Davis, B. M. & Molliver, D. C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat. Protoc. 2, 152-160 (2007).
52. Berman H. M. et al. The Protein Data Bank. Nucleic Acids Research 28, 235-242 (2000).
53. Lazaridis, T. & Karplus, M. Effective energy functions for protein structure prediction. Curr. Opin. Struct. Biol. 10, 139-145 (2000).
54. Andersen, H. C. Molecular dynamics simulations at constant pressure and/or temperature. J. Chem. Phys. 72, 2384-2393 (1980).
55. Kota, P., Ding, F., Ramachandran, S. & Dokholyan, N. V. Gaia: automated quality assessment of protein structure models. Bioinformatics 27, 2209-2215 (2011).
56. Wacker, D. et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 132, 11443-11445 (2010).
57. Lazaridis, T. & Karplus, M. Effective energy function for proteins in solution. Proteins 35, 133-152 (1999).
58. Zimmermann, M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109-110 (1983).
59. Tallarida, R. J. & Murray, R. B. In Manual of Pharmacologic Calculations. (Springer-Verlag New York, 1981).
60. Wieskopf, J. S. et al. Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene. Pain 155, 2063-70 (2014).